Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip

While the price of just about everything has increased over the last six years in the U.S., the same can’t be said for the cost of an FDA priority review voucher. Just ask Sarepta Therapeutics.

Since 2017, the Massachusetts rare disease specialist has sold off three PRVs—getting less in return for each one.

The most recent sale came Wednesday as Sarepta revealed a $102 million deal for its PRV that came along with the FDA’s endorsement two weeks ago of the company’s latest Duchenne muscular dystrophy (DMD) treatment, gene therapy Elevidys.